OPKO Health (OPK) to Release Earnings on Wednesday

OPKO Health (NASDAQ:OPK - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $163.13 million for the quarter.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Trading Down 1.1 %

Shares of OPKO Health stock traded down $0.02 on Monday, reaching $1.40. 568,776 shares of the company's stock were exchanged, compared to its average volume of 3,891,135. The company has a market capitalization of $936.81 million, a P/E ratio of -7.34 and a beta of 1.78. OPKO Health has a 52 week low of $1.15 and a 52 week high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm's 50-day moving average is $1.64 and its two-hundred day moving average is $1.57.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 67,434 shares of the company's stock in a transaction dated Friday, February 28th. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the acquisition, the chief executive officer now directly owns 213,301,448 shares of the company's stock, valued at $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have acquired 814,971 shares of company stock valued at $1,308,192. Corporate insiders own 49.69% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Barrington Research reissued an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Friday. They issued a "neutral" rating for the company. Finally, StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, OPKO Health has a consensus rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.